K J Morten1, M Caky, P M Matthews. 1. Institute of Molecular Medicine and Department of Clinical Neurology, University of Oxford, John Radcliffe Hospital, Headington, UK.
Abstract
OBJECTIVE: To test the effects of dichloroacetate (DCA) treatment on the rate of turnover of pyruvate dehydrogenase (PDH) subunits. BACKGROUND: PDH deficiency is a nuclear-encoded mitochondrial disorder and a major recognized cause of neonatal encephalomyopathies associated with primary lactic acidosis. DCA has been used for its treatment. The primary mechanism of action of DCA has been thought to increase the proportion of enzyme in the activated, dephosphorylated state. However, this mechanism does not readily account for responses to treatment with mutations that do not obviously affect regulation of the enzyme complex. METHODS: PDH subunit turnover rates were measured using pulse-chase methods in a normal fibroblastic cell line before and after chronic (5-day) treatment with 5 mM DCA. RESULTS: Chronic DCA treatment causes a more than twofold decrease in the apparent first-order rate constant for degradation of the PDH E1alpha subunit (kE1alpha(pre-DCA) = 0.025 +/- 0.006 hr(-1), n = 6; kE1alpha(post-DCA) = 0.011 /- 0.002 hr(-1), n = 3; p < 0.01) and a selective, progressive increase in the total cell PDH activity by 150 +/- 5% (p < 0.0005). CONCLUSION: These results suggest an additional novel mechanism of action for the chronic DCA treatment of lactic acidemia; namely, inhibition of mitochondrial E1alpha subunit degradation leading to an increase in maximal PDH complex activity.
OBJECTIVE: To test the effects of dichloroacetate (DCA) treatment on the rate of turnover of pyruvate dehydrogenase (PDH) subunits. BACKGROUND:PDH deficiency is a nuclear-encoded mitochondrial disorder and a major recognized cause of neonatal encephalomyopathies associated with primary lactic acidosis. DCA has been used for its treatment. The primary mechanism of action of DCA has been thought to increase the proportion of enzyme in the activated, dephosphorylated state. However, this mechanism does not readily account for responses to treatment with mutations that do not obviously affect regulation of the enzyme complex. METHODS:PDH subunit turnover rates were measured using pulse-chase methods in a normal fibroblastic cell line before and after chronic (5-day) treatment with 5 mM DCA. RESULTS: Chronic DCA treatment causes a more than twofold decrease in the apparent first-order rate constant for degradation of the PDH E1alpha subunit (kE1alpha(pre-DCA) = 0.025 +/- 0.006 hr(-1), n = 6; kE1alpha(post-DCA) = 0.011 /- 0.002 hr(-1), n = 3; p < 0.01) and a selective, progressive increase in the total cell PDH activity by 150 +/- 5% (p < 0.0005). CONCLUSION: These results suggest an additional novel mechanism of action for the chronic DCA treatment of lactic acidemia; namely, inhibition of mitochondrial E1alpha subunit degradation leading to an increase in maximal PDH complex activity.
Authors: Mandar A Joshi; Nam Ho Jeoung; Mariko Obayashi; Eyas M Hattab; Eric G Brocken; Edward A Liechty; Michael J Kubek; Krishna M Vattem; Ronald C Wek; Robert A Harris Journal: Biochem J Date: 2006-11-15 Impact factor: 3.857
Authors: Jun Xu; Feng Chi; Tongsheng Guo; Vasu Punj; W N Paul Lee; Samuel W French; Hidekazu Tsukamoto Journal: J Clin Invest Date: 2015-03-23 Impact factor: 14.808
Authors: Luana Naia; Teresa Cunha-Oliveira; Joana Rodrigues; Tatiana R Rosenstock; Ana Oliveira; Márcio Ribeiro; Catarina Carmo; Sofia I Oliveira-Sousa; Ana I Duarte; Michael R Hayden; A Cristina Rego Journal: J Neurosci Date: 2017-01-25 Impact factor: 6.167
Authors: Sihem Boudina; Heiko Bugger; Sandra Sena; Brian T O'Neill; Vlad G Zaha; Olesya Ilkun; Jordan J Wright; Pradip K Mazumder; Eric Palfreyman; Timothy J Tidwell; Heather Theobald; Oleh Khalimonchuk; Benjamin Wayment; Xiaoming Sheng; Kenneth J Rodnick; Ryan Centini; Dong Chen; Sheldon E Litwin; Bart E Weimer; E Dale Abel Journal: Circulation Date: 2009-02-23 Impact factor: 29.690